Key result
MMP and TIMP expression correlated with mitral insufficiency severity, being higher in mild cases and weaker in severe cases, and differed significantly between endocarditis and degenerative disease.
Why the study?
The pathogenesis of mitral valve insufficiency is not fully understood, prompting analysis of the role of selected matrix metalloproteinases and their inhibitors in the disease.
Is the expression of MMPs and TIMPs associated with the severity and etiology of mitral valve insufficiency?
Observational (n=80)
Is the expression of MMPs and TIMPs associated with the severity and etiology of mitral valve insufficiency?
Increased expression of MMPs and their inhibitors in mild mitral insufficiency suggests that molecular changes precede macroscopic and echocardiographic changes, potentially offering new avenues for early diagnosis.
MMP tissue expression may precede visible regurgitation severity; leaves open early biomarker potential pending prospective validation.
BACKGROUND: The pathogenesis of mitral valve insufficiency is not yet fully understood. Several studies stressed the role of matrix metalloproteinases (MMPs) in the emergence of valvular pathologies. The primary objective of the present study is to analyze the role of selected MMPs and their inhibitors in mitral valve insufficiency. PATIENTS AND METHODS: Eighty patients (33 female/47 male, mean age 67 years) underwent cardiopulmonary bypass surgery for mitral valve reconstruction between 2007 and 2015. All patients suffered from mitral insufficiency (MI) Stages iii and iv. When tissue resection was acquired specimens were taken immediately frozen and used for histological examination. Expression of MMP-1, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1, and TIMP-2 was examined immunohistochemically and distribution was analyzed in regard to preoperative clinical, echocardiographic, and histopathological findings. RESULTS: A clear correlation between the MMP expression and the MI degree of severity could be shown. The expression of MMPs proved to be high in relation to mild insufficiencies and relatively weak in the case of severe ones. Additionally, the etiology of the MI was considered in the analysis and a significant difference in the expression of MMPs between the mitral valves with endocarditis and the ones featuring a degenerative disease could be shown. Within the group of valves with degenerative diseases, no significant difference could be established between the subgroups (myxoid and sclerosed valves). CONCLUSION: The increased expression of MMPs and their inhibitors in mild insufficiencies could prove that the molecular changes in the valve precede the macroscopical and thus the echocardiographically diagnosable changes. Hence, new options for early diagnosis and therapy of MIs should be examined in further studies, respectively. Herein, the correlation of the MMP blood levels with MMP tissue expression should be addressed for surgical therapeutical decisions.
No takes yet. Share an insight, caveat, or question.
Irqsusi et al. (2022) conducted an observational in Mitral valve insufficiency (n=80). MMP-1, MMP-9, TIMP-1, and TIMP-2 expression was evaluated on Correlation between MMP expression and mitral insufficiency degree of severity and etiology. MMP and TIMP expression correlated with mitral insufficiency severity, being higher in mild cases and weaker in severe cases, and differed significantly between endocarditis and degenerative disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: